CID5721353
- Product Name
- CID5721353
- CAS No.
- 301356-95-6
- Chemical Name
- CID5721353
- Synonyms
- CID5721353;BCL6 inhibitor;79-6（CID5721353）;CID-5721353;CID 5721353;CID5721353, 10 mM in DMSO;CID5721353 BDL6 inhribitor;BCL6 inhibitor(CID5721353);CID5721353, BCL6 inhibitor;79-6 (CID5721353， BCL6 inhibitor);CID 5721353;CID-5721353;CID 5721353
- CBNumber
- CB53159456
- Molecular Formula
- C15H9BrN2O6S2
- Formula Weight
- 457.28
- MOL File
- 301356-95-6.mol
CID5721353 Property
- Density
- 2.06±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 3.02±0.23(Predicted)
- color
- Light brown to brown
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 22967
- Product name
- CID-5721353
- Packaging
- 1mg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 22967
- Product name
- CID-5721353
- Packaging
- 5mg
- Price
- $70
- Updated
- 2024/03/01
- Product number
- 22967
- Product name
- CID-5721353
- Packaging
- 10mg
- Price
- $109
- Updated
- 2024/03/01
- Product number
- 22967
- Product name
- CID-5721353
- Packaging
- 25mg
- Price
- $190
- Updated
- 2024/03/01
- Product number
- 6486CL
- Product name
- 2-[5-(5-Bromo-2-oxoindol-3-yl)-4-hydroxy-2-sulfanylidene-1,3-thiazol-3-yl]butanedioicacid
- Packaging
- 5mg
- Price
- $313
- Updated
- 2021/12/16
CID5721353 Chemical Properties,Usage,Production
Description
CID-5721353 is an inhibitor of the transcriptional repressor B cell lymphoma 6 (Bcl-6; Ki = 147 μM). It is selective for Bcl-6 over Kaiso, hypermethylated in cancer 1 (HIC1), and promyelocytic leukemia zinc finger (PLZF) at 50 μM. CID-5721353 is cytotoxic against Bcl-6-dependent SU-DLH-6, SU-DLH-4, Farage, OCI-LY7, OCI-LY1, and OCI-LY10 diffuse large B cell lymphoma (DLBCL) cells (GI50s = 0.024-0.936 mM) but not Bcl-6-independent Toledo or OCI-LY4 DLBCL cells (GI50 = >15 mM for both). It increases expression of the Bcl-6 target genes ATR, TP53, CD69, p21, and CD44 in SU-DLH-6 and SU-DHL-4 cells when used at a concentration of 50 μM. CID-5721353 (50 mg/kg) reduces tumor growth in OCI-LY7 and SU-DHL-6 mouse xenograft models.
Uses
CID5721353 is an inhibitor of BCL6 with an IC50 value of 212 μM, which corresponds to a Ki of 147 μM.
in vivo
In order to test whether CID5721353 (Compound 79-6) can perform as an anti-lymphoma therapeutic agent in vivo, whether it can penetrate tumors after parenteral administration through a distal site is determined. For this purpose 107OCI-Ly7 cells are injected into the right flank of 10 SCID mice and allowed to form tumors. Once tumors reach ~1.5 grams, animals are injected IP with a single dose of 50 mg/kg of CID5721353 in 10% DMSO or vehicle (10% DMSO) and sacrificed at 0.5, 1, 1.5, 3, 6, 12 and 24 hours after CID5721353 administration. Blood and tumors are harvested. Quantitative HPLC/MS analysis of the serum shows that CID5721353 levels peak (to 55 μg/mL, which is equivalent to a 122 μM concentration) one hour after the IP injection. CID5721353 also reaches its highest peak (24.5 ng/mg) at the 1-hour time point in the tumors, and after a sharp decline in levels, decreases gradually over 24 hours[1].
References
[1] Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010 Apr 13;17(4):400-11. DOI:10.1016/j.ccr.2009.12.050
CID5721353 Preparation Products And Raw materials
Raw materials
Preparation Products
CID5721353 Suppliers
View Lastest Price from CID5721353 manufacturers
- Product
- CID5721353 301356-95-6
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 97%-99.9%
- Supply Ability
- 100kg
- Release date
- 2019-12-25